Jul 8, 2026 · 10 min · 6 segments
At the University of California, San Francisco (UCSF), the team treating patients with bladder cancer and other genitourinary malignancies utilizes a multidisciplinary team approach to ensure care is…
Iva ColónGuest
Terence FriedlanderGuestSummer JohnsonHostWhen did UCSF begin administering ADCs for bladder cancer and what was that onboarding and preparation process like for your staff?
So, you know, we first got interested in ADCs probably in like 2017, 2018 as the first of these were being developed in bladder cancer.
There were really two agents, infortimab, vedotin, sasituzumab, govatican, which really kind of hit clinical trials around the same time around then.
So we became interested in that from a clinical trials perspective because we'd seen early phase studies that had suggested you know, pretty strong benefit.
And we really wanted to give that, you know, treatment, that opportunity to our patients.
When did UCSF begin administering ADCs for bladder cancer and what was that onboarding and preparation process like for your staff?
So, you know, we first got interested in ADCs probably in like 2017, 2018 as the first of these were being developed in bladder cancer.
There were really two agents, infortimab, vedotin, sasituzumab, govatican, which really kind of hit clinical trials around the same time around then.
So we became interested in that from a clinical trials perspective because we'd seen early phase studies that had suggested you know, pretty strong benefit.
And we really wanted to give that, you know, treatment, that opportunity to our patients.
The rest of this transcript — segmented and speaker-labeled, so you land on the exact moment something was said
Search every transcript — by keyword, by phrase, or by meaning, across every show Radar indexes
Trends — what is surging across podcasts, measured against its own baseline
Alerts — when a name you follow appears in a newly indexed episode
No account is needed to search Radar.
